Skip to main content
RXR modulators to improve the efficacy of immunomodulatory agents in multiple myeloma treatment

RXR modulators to improve the efficacy of immunomodulatory agents in multiple myeloma treatment

Unmet Need Multiple myeloma (MM) is the second most common hematological malignancy in the United States. Although current anti-myeloma therapeutics help patients live with the disease for more than 10 years, MM remains an incurable…

Read More

Pancreatic cancer treatment that inhibits the Piezo1/TRPV4 axis

Pancreatic cancer treatment that inhibits the Piezo1/TRPV4 axis

Unmet Need Pancreatic cancer has one of the highest mortality rates of all cancer types in the US. The American Cancer Society predicts that about 64,000 people will be diagnosed with pancreatic cancer and 55,000…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us